282 related articles for article (PubMed ID: 25088482)
1. Ovarian function preservation with GnRH agonist in young breast cancer patients: does it impede the effect of adjuvant chemotherapy?
Kim J; Kim M; Lee JH; Lee H; Lee SK; Bae SY; Jun SY; Kil WH; Lee JE; Kim SW; Nam SJ
Breast; 2014 Oct; 23(5):670-5. PubMed ID: 25088482
[TBL] [Abstract][Full Text] [Related]
2. Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy.
Kim HJ; Lee MH; Lee JE; Park S; Lee ES; Kang YJ; Shin HN; Kim SI; Lee JH; Im SA; Ahn SH; Lee KS; Sohn J; Kim S; Nam SJ; Han W
Clin Breast Cancer; 2018 Oct; 18(5):e1165-e1172. PubMed ID: 29843988
[TBL] [Abstract][Full Text] [Related]
3. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Moore HC; Unger JM; Phillips KA; Boyle F; Hitre E; Porter D; Francis PA; Goldstein LJ; Gomez HL; Vallejos CS; Partridge AH; Dakhil SR; Garcia AA; Gralow J; Lombard JM; Forbes JF; Martino S; Barlow WE; Fabian CJ; Minasian L; Meyskens FL; Gelber RD; Hortobagyi GN; Albain KS;
N Engl J Med; 2015 Mar; 372(10):923-32. PubMed ID: 25738668
[TBL] [Abstract][Full Text] [Related]
4. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
Urruticoechea A; Arnedos M; Walsh G; Dowsett M; Smith IE
Breast Cancer Res Treat; 2008 Aug; 110(3):411-6. PubMed ID: 17851753
[TBL] [Abstract][Full Text] [Related]
5. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996
[TBL] [Abstract][Full Text] [Related]
6. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A
Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312
[TBL] [Abstract][Full Text] [Related]
7. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials.
Yang B; Shi W; Yang J; Liu H; Zhao H; Li X; Jiao S
Breast; 2013 Apr; 22(2):150-157. PubMed ID: 23298851
[TBL] [Abstract][Full Text] [Related]
8. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of leuprolide on ovarian function in young women treated with adjuvant chemotherapy for early breast cancer: a multicenter phase II study.
Maisano R; Caristi N; Mare M; Bottari M; Adamo V; Mafodda A; Calogero MG; Caruso M; Nardi M
J Chemother; 2008 Dec; 20(6):740-3. PubMed ID: 19129073
[TBL] [Abstract][Full Text] [Related]
10. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.
Bildik G; Akin N; Senbabaoglu F; Sahin GN; Karahuseyinoglu S; Ince U; Taskiran C; Selek U; Yakin K; Guzel Y; Ayhan C; Alper E; Cetiner M; Balaban B; Mandel NM; Esen T; Iwase A; Urman B; Oktem O
Hum Reprod; 2015 Dec; 30(12):2912-25. PubMed ID: 26466909
[TBL] [Abstract][Full Text] [Related]
11. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
12. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
Leonard RCF; Adamson DJA; Bertelli G; Mansi J; Yellowlees A; Dunlop J; Thomas GA; Coleman RE; Anderson RA;
Ann Oncol; 2017 Aug; 28(8):1811-1816. PubMed ID: 28472240
[TBL] [Abstract][Full Text] [Related]
13. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis.
Vitek WS; Shayne M; Hoeger K; Han Y; Messing S; Fung C
Fertil Steril; 2014 Sep; 102(3):808-815.e1. PubMed ID: 25044080
[TBL] [Abstract][Full Text] [Related]
15. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
Torrisi R; Bagnardi V; Rotmensz N; Scarano E; Iorfida M; Veronesi P; Luini A; Viale G; Santoro A; Colleoni M; Goldhirsch A
Breast Cancer Res Treat; 2011 Apr; 126(2):431-41. PubMed ID: 21221766
[TBL] [Abstract][Full Text] [Related]
16. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
17. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
19. Use of goserelin in the treatment of breast cancer.
Rody A; Loibl S; von Minckwitz G; Kaufmann M
Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
[TBL] [Abstract][Full Text] [Related]
20. Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature.
Hill N; Madarnas Y
Breast Cancer Res Treat; 2011 Aug; 129(1):265-8. PubMed ID: 21541703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]